Bedside CAR-T therapy takes on leukemia in early safety trial
NCT ID NCT07277504
First seen Jan 04, 2026 · Last updated May 09, 2026 · Updated 19 times
Summary
This early-phase study tests a new CAR-T cell therapy made at the bedside for adults with B-cell acute lymphoblastic leukemia. The main goal is to check safety and find the best dose. Fifty participants will receive the treatment and be closely monitored for side effects and how well the leukemia responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
The General Hospital of Western Theater Command
Chengdu, Sichuan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.